Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

ABSTRACT:

Objectives

To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts (condyloma acuminata).

Design

Data from two international, double blind, placebo controlled, randomised efficacy trials of quadrivalent HPV vaccine (protocol 013 (FUTURE I) and protocol 015 (FUTURE II)). The trials were to be 4 years in length, and the results reported are from final study data of 42 months' follow-up.

Setting

Primary care centres and university or hospital associated health centres in 24 countries and territories around the world.

Participants

17 622 women aged 16-26 years enrolled between December 2001 and May 2003. Major exclusion criteria

SUBMITTER: FUTURE I/II Study Group 

PROVIDER: S-EPMC2907480 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature